This #MemorialDay we pause to honor the men and women who have made the ultimate sacrifice for our freedom. #WeRemember

The second half of 2022 is shaping up to be very busy. Read this week's press release reporting Q2 financial & operating results and a business update. investors.eloxxpharma.com/news-releases/… #RareDisease #cysticfibrosis #alportsyndrome

Eloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of #AlportSyndrome. Learn more in today's press release: investors.eloxxpharma.com/news-releases/…

$ELOX Eloxx Pharmaceuticals making progress on Phase 2 Clinical Study for ELX-02 Alport syndrome candidate tinyurl.com/2ehwjfq7 Eloxx Pharmaceuticals #ELOX

In conjunction with #RareDiseaseDay, we announce initiation of Phase 2 clinical study of ELX-02 for the treatment of #AlportSyndrome with the first patients being dosed. Read the press release and learn about our unique ribosome-modulating technology. investors.eloxxpharma.com/news-releases/…

Join us on Monday, March 13th at 12:00 PM ET as we present at the Oppenheimer & Co. Inc. 33rd Annual Healthcare Conference. A live webcast and replay of the presentation will be available on our website: lnkd.in/g6cJBGTR

This week, we announced submission of Investigational New Drug (IND) Application for ZKN-013. Read the press release here: investors.eloxxpharma.com/news-releases/…

Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update. View press release here: investors.eloxxpharma.com/news-releases/…

We're encouraged by prelim data from our proof-of-concept study of ELX-02 in #AlportSyndrome & expect to deliver topline data in first 1/2 of the year. This rare genetic disorder is characterized by kidney disease w/ high levels of proteinuria, hearing loss & eye abnormalities.

Eloxx is pleased to announce plans to initiate a first in human study of ZKN-013 in patients with RDEB. #RDEB is a rare, inherited, and life-threatening genetic disorder in which collagen VII is missing. Read full press release: investors.eloxxpharma.com/news-releases/…

We are pleased to share initial results of our phase 2 study in #AlportSyndrome. View the press release here: investors.eloxxpharma.com/news-releases/…

Grateful to Nasdaq for extending the deadline on Listing Rule 5550(b)(2). Our pipeline has tremendous momentum w/ potential to treat rare genetic diseases harboring nonsense mutations. View press release: investors.eloxxpharma.com/news-releases/…

This week, we share highlights from the recent Alport syndrome natural history data presented at the 60th European Renal Association (ERA) Congress. Read more: investors.eloxxpharma.com/news-releases/…

Not all types of Alport syndrome are the same. Patients w/ certain mutations progress to end-stage renal disease faster than others. At Eloxx, we’re working to address the most serious forms of #Alportsyndrome. Learn more about our focus in this area: lnkd.in/g3EeFMzp

Alport syndrome is a #raredisease affecting 30k – 60k ppl and the cause of roughly 3% of children w/ chronic kidney disease. Eloxx is committed to advancing treatments for those with #AlportSyndrome due to nonsense mutations. Learn more from the National Kidney Foundation kidney.org/atoz/content/a…

#AlportSyndrome w/ nonsense mutations is a rare genetic disorder found in 1 in 50K newborns in the US. We're focused on helping this population and intend to advance ELX-02 into pivotal trial in 2023. eloxxpharma.com/alport-syndrom…

Community support is important for anyone living with a rare disease. Patients & families impacted by #AlportSyndrome have the opportunity to come together in Oct @ the Alport Connect meeting hosted by the Alport Syndrome Foundation. Learn more: alportsyndrome.org/for-patients/a…

Alport syndrome is signaled by blood and protein in the patient's urine, and characterized by progressive kidney disease, hearing loss, and eye abnormalities. Learn more about #AlportSyndrome and our commitment to help those with nonsense mutations. eloxxpharma.com/alport-syndrom…

Compelling kidney biopsy data from the development of ELX-02 supports the advancement of a pivotal trial for the treatment of #AlportSyndrome. See the press release: investors.eloxxpharma.com/news-releases/…

This week, Eloxx reported positive Q2 financial and operating results along with upcoming 2023 investigational plans for Alport Syndrome and RDEB (recessive dystrophic epidermolysis bullosa). Click to view the full release: investors.eloxxpharma.com/news-releases/…